Home

Insights

PE

Ajanta Pharma Ltd P/E Ratio

Ajanta Pharma Ltd P/E Ratio

download
stocks purchased

₹ 1.1 Cr

Volume transacted

stocks purchased

5.1 K

stocks traded

Last Updated time: 15 Jul 13:05 PM

Image

Ajanta Pharma Ltd

NSE: AJANTPHARM

PE

34.4

Last updated : 15 Jul 13:05 PM

Key Highlights

    The P/E Ratio of Ajanta Pharma Ltd is 34.4 as of 15 Jul 13:05 PM .a1#The P/E Ratio of Ajanta Pharma Ltd changed from 23.4 on March 2019 to 34.7 on March 2024 . This represents a CAGR of 6.79% over 6 years. a1#The Latest Trading Price of Ajanta Pharma Ltd is ₹ 2244 as of 15 Jul 12:58 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Ajanta Pharma Ltd changed from ₹ 8990 crore on March 2019 to ₹ 28181 crore on March 2024 . This represents a CAGR of 20.97% over 6 years. a1#The Revenue of Ajanta Pharma Ltd changed from ₹ 983.69 crore to ₹ 1089 crore over 8 quarters. This represents a CAGR of 5.24% a1#The EBITDA of Ajanta Pharma Ltd changed from ₹ 254.52 crore to ₹ 313.82 crore over 8 quarters. This represents a CAGR of 11.04% a1#The Net Pr of Ajanta Pharma Ltd changed from ₹ 174.62 crore to ₹ 202.72 crore over 8 quarters. This represents a CAGR of 7.75% a1#The Dividend Payout of Ajanta Pharma Ltd changed from 20.17 % on March 2019 to 79.83 % on March 2024 . This represents a CAGR of 25.77% over 6 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Ajanta Pharma Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Ajanta Pharma Ltd

Period
Mar '1923.4
Mar '2025.6
Mar '2123.9
Mar '2221.8
Mar '2326
Mar '2434.7

Company Fundamentals for Ajanta Pharma Ltd

Market Cap

27,795 Cr

EPS

64.2

P/E Ratio (TTM) *

34.4

P/B Ratio (TTM) *

7.8

Day’s High

2250.4

Day’s Low

2199.55

DTE *

0.0

ROE *

22.9

52 Week High

2531.95

52 Week Low

1391.0

ROCE *

31.1

* All values are consolidated

Last Updated time: 15 Jul 13:05 PM

* All values are consolidated

Last Updated time: 15 Jul 13:05 PM

Image

Ajanta Pharma Ltd

NSE: AJANTPHARM

PRICE

2244

36.60 (1.66%)

stock direction

Last updated : 15 Jul 12:58

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Ajanta Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Ajanta Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Ajanta Pharma Ltd

Market Value

27,795

Asset Value

2,570

9.8 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Ajanta Pharma Ltd3427,795
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Ajanta Pharma Ltd

Earnings

816 Cr

34.4 X

PE Ratio

Market Cap

₹27795Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

816 Cr

34.4 X

PE Ratio

Market Cap

₹27795Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Ajanta Pharma Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Ajanta Pharma Ltd

Period
Mar '198991
Mar '2011922
Mar '2115517
Mar '2215453
Mar '2315490
Mar '2428181

* All values are a in crore

×

Historical Revenue of Ajanta Pharma Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Ajanta Pharma Ltd

Period
Jun '22984
Sep '22978
Dec '221007
Mar '23919
Jun '231053
Sep '231050
Dec '231119
Mar '241090

* All values are a in crore

×

Historical EBITDA of Ajanta Pharma Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Ajanta Pharma Ltd

Period
Jun '22255
Sep '22237
Dec '22204
Mar '23186
Jun '23303
Sep '23312
Dec '23328
Mar '24314

* All values are a in crore

×

Historical Net Profit of Ajanta Pharma Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Ajanta Pharma Ltd

Period
Jun '22175
Sep '22157
Dec '22135
Mar '23122
Jun '23208
Sep '23195
Dec '23210
Mar '24203

* All values are a in crore

×

Historical Dividend Payout of Ajanta Pharma Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Ajanta Pharma Ltd

Period
Mar '1920
Mar '2026
Mar '2112
Mar '2211
Mar '2316
Mar '2480

* All values are a in %

About Ajanta Pharma Ltd

About Ajanta Pharma Ltd

    Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management. In branded generic business in emerging markets in Asia and Africa, Ajanta Pharma's products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The company's institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa. Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been successfully approved by US FDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Its R&D centre has a team of over 750 scientists working on innovative products for various markets across the globe. Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up its 1stManufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period from 1995 to 1998, the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its Paithan manufacturing facility in 2008. In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. During the year, the company bought a manufacturing facility at Chitegaon in Aurangabad, Maharashtra to fuel the company's growth. Also during the year, Ajanta Pharma became the first generic company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug. In 2010, Ajanta Pharma entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc. In 2011, Ajanta Pharma emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions. In 2012, Ajanta Pharma was ranked among the Top 10 pharma companies in Franco Africa. During the year 2013, Ajanta Pharma commenced sales to the US market. In 2014, the company set up its 2nd dedicated R&D centre at Kandivli in Mumbai for India and emerging markets. During the year, the company inaugurated a new facility in Dahej, Bharuch, Gujarat for catering to the requirements of markets like USA, WHO and emerging markets. In 2015, the company announced the launch of Montelukast Sodium Oral Granules. The company also announced the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market. In 2017, the company inaugurated and commissioned 1st phase at a new facility in Guwahati, Assam. The company's Dahej, Gujarat facility was approved by the USFDA without any observation in April 2017. On 11 July 2017, Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma (APL) informed the company that promoters have sold 27 lakh equity shares in APL, representing about 3.07% of APL's equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% in APL. This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use. On 9 February 2018, Ajanta Pharma announced that its formulation facility at Dahej in Gujarat was inspected by USFDA from 5 to 9 February 2018. At the end of the inspection, no Form 483 was issued to the company by the USFDA. As on 31 March 2018,the company has six subsidiaries overseas, including one step down subsidiary under its roof. The company's capex investment in manufacturing facilities and R&D which has taken the total from Rs 997 crore in FY 2017 to Rs 1,225 crore in FY 2018. The Company had convened Extra-Ordinary General Meeting on 10th October 2017 as per the directions of National Company Law Tribunal for obtaining consent of shareholders for merger of 'Gabs Investments Private Ltd. ' with the Company. During the FY2019, company's wholly owned subsidiary viz., Ajanta Pharma UK Limited was dissolved on 18th December 2018. Post that, the company has five operating subsidiaries overseas, including one step down subsidiary. The total capex for FY 2019 was Rs 361 crore and propose to spend further Rs 350 crore in FY 2020, mainly on Guwahati, Pithampur and corporate office in Mumbai. in March 2019, the Company bought back 7,69,230 (Seven lakhs sixty-nine thousand two hundred and thirty only) fully paidup equity shares of the face value of Rs 2/- each at a price of Rs 1300 per share for an aggregate amount of Rs 100 crore. The Scheme of Amalgamation and Arrangement of Gabs Investments Pvt. Ltd. with the Company which was filed by the Company with National Company Law Tribunal (NCLT) in the last year, was rejected by NCLT on grounds cited in its order. The Company had preferred an appeal before the National Company Law Appellate Tribunal (NCLAT) challenging the order of NCLT. However, after considering all the pros and cons at length, it was deemed appropriate to withdraw the appeal. Accordingly, the same was withdrawn on 7th December 2018. During the FY2020, third phase of Guwahati plant, new manufacturing facility in Pithampur, Madhya Pradesh and new R & D building in Kandivli, Mumbai were completed and became fully functional. Expansion of facility at Dahej has been commenced and the same is expected to be over by December 2020. During the year, an amount of Rs 245 crore was incurred on capex. The Board of Directors have approved buyback proposal on 3 November 2020, for purchase by the Company of up to 7,35,000 shares of Rs 2 each (representing 0.84% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of Rs 1,850 per equity share for an aggregate amount not exceeding Rs 135.98 crore in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018. During the quarter ended 31 December 2020,the group had bought back its 735000 equity shares of Rs 2/-each at Rs 1850 per share for an aggregate amount of Rs 135.98 crore and extinguished those shares on 30 December 2020. The Company launched 16 new products in FY 2022, including four 1st to market products in the country. During the year 2022, it launched 3 new products and filed 8 ANDAs. It received 2 final and 1 tentative approval. There are 20 ANDAs awaiting approval from US FDA. The Company launched 23 new products in FY 2023 with six first-to-market products.

Ajanta Pharma Ltd News Hub

News

Ajanta Pharma AGM scheduled

Ajanta Pharma announced that the 45th Annual General Meeting (AGM) of the company will be ...

Read more

15 Jun 202410:25

News

Ajanta Pharma spurts as Q4 PAT climbs 66% YoY, board OKs Rs 285-cr share buyback

Profit before tax soared 82.86% to Rs 278.04 crore in Q4 FY24 from Rs 152.05 crore reporte...

Read more

03 May 202410:22

News

Volumes jump at Ajanta Pharma Ltd counter

Coforge Ltd, Cummins India Ltd, Torrent Pharmaceuticals Ltd, Bajaj Finserv Ltd are among t...

Read more

03 May 202411:00

News

Volumes spurt at Ajanta Pharma Ltd counter

Coforge Ltd, Piramal Pharma Ltd, Kansai Nerolac Paints Ltd, Elgi Equipments Ltd are among ...

Read more

03 May 202414:30

News

Ajanta Pharma to table results

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 2 May 2024. ...

Read more

22 Apr 202416:40

News

Ajanta Pharma PAT jumps 56% YoY to Rs 210 cr in Q3 FY24

Revenue from operations jumped 13.72% year on year (YoY) to Rs 1,105.15 crore in the quart...

Read more

01 Feb 202411:29

Product Composition by Percentage (Revenue)

FAQs for PE of Ajanta Pharma Ltd

What is Ajanta Pharma Ltd current share price?

The current market price of Ajanta Pharma Ltd as of July 15, 2024 is ₹2244.00.

Is Ajanta Pharma Ltd a good investment?

As per BlinkX Score Ajanta Pharma Ltd scores 67 in Revenue, 64 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Ajanta Pharma Ltd's total net assets?

According to Ajanta Pharma Ltd's most recent financial filings, the company's net assets total ₹2570.3 Cr.

Is Ajanta Pharma Ltd making a profit or loss?

Ajanta Pharma Ltd's net Profit as of July 15, 2024 is close to ₹816 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199